News
Gilead Sciences Inc. Still Singing the HCV Blues in the 3rd Quarter
Surprisingly strong hepatitis C virus (HCV) sales helped Gilead Sciences (NASDAQ: GILD) enjoy better-than-expected results when the big biotech provided its second-quarter update in July. But that....
Was Celgene’s Third Quarter Really Crash-Worthy?
On the heels of reporting a disappointing late-stage trial failure, Celgene Corp. (NASDAQ: CELG) issued a poor third-quarter financial report that's stoking investors' fears. Has the biotech lost....
The Clear Reason Alkermes Plc's Shares Jumped by as Much as 12%
Shares of Alkermes (NASDAQ: ALKS), an Irish-based commercial-stage drug developer with a focus on central nervous system medicines, jumped by as much as 12% during Thursday's trading session and....
The Double Whammy That Sent Marijuana Stock Insys Therapeutics Crashing as Much as 30%
Shares of Insys Therapeutics (NASDAQ: INSY), a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy. One whammy was the arrest of....
Oh Baby! Natus Medical Inc. Beats and Raises Guidance
Natus Medical (NASDAQ: BABY) continues its turnaround, hitting its third-quarter revenue guidance and beating its own expectations for adjusted earnings, which were forecast to be in the range of....
Abiomed, Inc's Revenue and Profits Soar Yet Again
Abiomed (NASDAQ: ABMD), a medical-device maker focused on minimally invasive heart pumps, reported its fiscal second-quarter earnings on Thursday, Oct. 26. The company once again reported strong....
Abiomed, Inc's Revenue and Profits Soar Yet Again
Abiomed (NASDAQ: ABMD), a medical-device maker focused on minimally invasive heart pumps, reported its fiscal second-quarter earnings on Thursday, Oct. 26. The company once again reported strong....
Alkermes Reports Mixed Results, Updates Guidance
Alkermes (NASDAQ: ALKS), a commercial-stage biopharmaceutical company focused on diseases of the central nervous system, reported its third-quarter earnings results on Thursday, Oct. 26. While....
Should You Be Worried After Bristol-Myers Squibb's Q3 Results?
It's been an up-and-down kind of year for Bristol-Myers Squibb (NYSE: BMY). Early in 2017, investors were concerned after the company opted not to pursue accelerated approval for a combination of....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
3 Dividend Stocks Perfect for Retirement
Retirement is a time to shift one's investment portfolio to a more defensive posture. If this can be done while generating income via dividend payouts, so much the better. We asked three of our....
Why Celgene Corporation Tumbled Today
Celgene (NASDAQ: CELG) is down 18.2% at 12:11 p.m. Thursday after releasing third-quarter earnings. It wasn't so much third-quarter revenue, which was up 10% year over year, or the adjusted....
Here's Why Idera Pharmaceuticals Plunged as Much as 35% Today
Shares of pre-revenue biopharma Idera Pharmaceuticals (NASDAQ: IDRA) sank as much as 35% this morning after the company announced the pricing of a major public stock offering. The company will....
5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a....
5 Things You'll Want to Watch With AbbVie's Q3 Results
If 2017 ended right now, it would go down as AbbVie's (NYSE: ABBV) best ever. The biotech stock's price has risen a little more than the 50% gains AbbVie made during its first year as a....
Price Hikes Insulate Celgene From a Failure
After independent monitors concluded a phase 3 trial of GED-301 in Crohn's disease was a failure, Celgene (NASDAQ: CELG) shelved its plans to develop this drug for use in that billion-dollar....
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....
What's Behind Amgen's Q3 Revenue Decline
When Amgen (NASDAQ: AMGN) announced its second-quarter results in July, the anemic revenue growth was overshadowed by the company's solid earnings increase and its improved full-year guidance. CEO....
Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.The....
Why MacroGenics, Inc. Stock Soared Today
Shares of the clinical-stage oncology and autoimmune disease specialist MacroGenics (NASDAQ: MGNX) ended the day higher by a healthy 17.36% on a whopping 17.5 times the average volume.The....
Why Did Innoviva, Inc. Stock Fall Nearly 16% Wednesday?
Shares of bio-pharmaceutical company Innoviva (NASDAQ: INVA) fell as much as 17.4% on Wednesday. But the stock finished the trading day down 15.55%.The stock's decline came just before Innoviva....
Here's Why NuVasive, Inc. Popped Today
Shares of NuVasive, Inc. (NASDAQ: NUVA), a spinal-surgery device manufacturer, popped as high as 9.8% Wednesday morning before settling back down to an 8.1% gain as of 3:07 p.m. A mixed....
Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise
Biogen (NASDAQ: BIIB) grew earnings faster than revenue in the third quarter, which is what investors should be looking for from any mature company in their portfolio. Nevertheless, shares went....
Biogen Inc Content With "Resilience" of Its Multiple Sclerosis Franchise
Biogen (NASDAQ: BIIB) grew earnings faster than revenue in the third quarter, which is what investors should be looking for from any mature company in their portfolio. Nevertheless, shares went....